
Ocular Therapeutix, Inc.: updates and filings
Price
$5.94
November 18, 2026Market cap $1.3B
What Ploutos Investor adds for Ocular Therapeutix
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
February 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Shares registered for employeesFormS-8
- Nov 9, 2026Officer or director changeForm8-K
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 16, 2026Officer or director changeForm8-K
- Aug 3, 2026Shares registered for employeesFormS-8
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 12, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 27, 2026Regulation FD disclosureForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 5, 2026Shares registered for employeesFormS-8
- Feb 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 5, 2026Results of operationsForm8-K
- Jan 23, 2026Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | S-8 | Shares registered for employees | Document |
| Nov 9, 2026 | 8-K | Officer or director change | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 16, 2026 | 8-K | Officer or director change | Document |
| Aug 3, 2026 | S-8 | Shares registered for employees | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 27, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 5, 2026 | S-8 | Shares registered for employees | Document |
| Feb 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 5, 2026 | 8-K | Results of operations | Document |
| Jan 23, 2026 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 6, 2007.
The full analysis
What do Ocular Therapeutix's filings show?
The filings are where every one of Ocular Therapeutix's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.